Drugs / Ftortiazinon
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03638830 | Oct 2018 → Nov 2022 | Pseudomonas aeruginosa infectious disease, bacterial urinary tract infection | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ftortiazinon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03638830 ↗ |
| Route | Oral | “the patients will take the drug Ftortiazinon tablets 300 mg” NCT03638830 ↗ |